NHI to reimburse Zeffix for liver sclerosis and hepatitis
Published: 2005-09-08 07:00:00
Updated: 2005-09-08 07:00:00
The NHI reimbursement of Zeffix (lamivudine) and Hepsera (adefovir) will be granted for the chronic B hepatitis patients accompanied with hepatitis and liver sclerosis for maximum 2 years when showing the e-antigen and HBV-DNA test every 3 month.
GSK said on Sept. 5 that the patients with live...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
